| Biomarker ID | 1405 |
| PMID | 24737792 |
| Year | 2014 |
| Biomarker | OAZ2 |
| Biomarker Basis | RNA expression |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Downregulated in PCa |
| Odds Ratio/Hazard Ratio/Relative Risk | Cohort 1 : Univariate: HR: 56.76 (95% CI: 9.04-356.44), p-value <0.001, C-Index= 0.68; Multivariate: HR= 123.41 (95% CI:1.34-11383.85), p-value= 0.037, C-Index=0.85; |
| Effect on Pathways | Pathways include: Ubiquitin-mediated degradation of phosphorylated Cdc25A; Amino acid metabolism |
| Experiment | Biochemical recurrence Vs No Biochemical Recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 30 nonmalignant and 30 prostate cancer tissue samples were used for this analysis |
| Senstivity | 95.5% |
| Specificity | 94.3% |
| AUC | 0.98 |
| Accuracy | NA |
| Level Of Significance | p=0.001 |
| Method Used | Training: Microarray; Validation: qRT-PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NA |